FDA Import Refusal 1FX-3971449-9/10002/2 — Astrazeneca Pharma India Ltd
The FDA refused shipment 1FX-3971449-9/10002/2 from Astrazeneca Pharma India Ltd (India) on Sep 18, 2026. The refused product falls under Drugs and Biologics — DAPAGLIFLOZIN (ANTI-DIABETIC). Cited charges: 118,75 This firm has 5 or more other import refusals on record.
Refusal Details
- Date
- Sep 18, 2026
- Country
- India
- Product Category
- Drugs and Biologics
- Product Code
- 61PDA70 DAPAGLIFLOZIN (ANTI-DIABETIC)
- Charges
- 118,75